Urologists discuss the importance of monitoring cardiovascular health in patients undergoing androgen deprivation therapy for prostate cancer. This episode, titled ‘Ongoing ADT Monitoring and ...

Healthcare professionals discuss the vital role of pharmacy teams in managing complex patient care, emphasizing collaboration and medication safety. In this episode, ‘The Role of Pharmacy in ...

Enolen's fast track designation by the FDA highlights its potential to address unmet needs in early-stage prostate cancer treatment. The implant technology aims to deliver high local drug ...

The Altaviva device offers a minimally invasive treatment for urge urinary incontinence, with patients returning home with therapy activated. It features a 15-year battery lifespan, MRI compatibility, ...

ArteraAI Prostate is the first AI tool authorized to prognosticate long-term outcomes in localized prostate cancer, using multimodal AI technology. The FDA's de novo authorization allows ...

"As with all medications and services, it is important to check with the patient’s insurer to determine their policy and whether the medication will be covered," write Jonathan Rubenstein, MD, and ...

The TOBY Test uses AI and gas chromatography–mass spectrometry to analyze urine for early cancer detection, offering a significant advantage over current methods. The FDA's breakthrough device ...

Neuspera's iSNM system provides a battery-free alternative to traditional SNM, reducing complications and surgeries for UUI patients. The SANS-UUI trial showed 84.2% of patients achieved at least a 50 ...

Expert panel developed guidelines for onabotulinumtoxinA use in OAB, emphasizing patient experience and compliance. Recommendations cover patient counseling, pre-procedure urinalysis, antibiotic use, ...

Nivolumab plus ipilimumab improved overall survival and response rates over sunitinib in advanced renal cell carcinoma, with a median follow-up of 9.3 years. The combination showed sustained benefits ...

UGN-102's NDA is supported by the phase 3 ENVISION trial, showing a 79.6% complete response rate at 3 months for LG-IR-NMIBC patients. The FDA is evaluating if the observed duration of response is due ...

The first successful human bladder transplant was performed by USC and UCLA surgeons, marking a significant medical milestone. The patient, previously on dialysis, showed immediate improvement ...